NOX 1.52% 6.7¢ noxopharm limited

Patent Update

  1. RBx
    643 Posts.
    lightbulb Created with Sketch. 1002
    Noxopharm has replied to the USPTO requirement to refine their patent application
    IMPROVEMENTS IN CANCER TREATMENT
    by defining Idronoxil as their 'elected species'.

    Any claims for other species that were withdrawn can be pursued in subsequent applications.

    Moving forward, as expected.  Harvett will no doubt take exception, but who cares?
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.